機関投資家は,インサイダーセールにもかかわらず, 強い利益と上昇予測の後,エドワーズ・ライフサイエンスの保有額を増加させた. Institutional investors increased holdings in Edwards Lifesciences after strong earnings and raised guidance, despite insider selling.

機関投資家のHolocene AdvisorsとHudson Bay Capitalは,第2四半期にエドワーズ・ライフサイエンスへの投資を拡大し,第3四半期に0.67ドルのEPSと155億ドルの収益で,同比14.7%の上昇を挙げました. Institutional investors Holocene Advisors and Hudson Bay Capital boosted their stakes in Edwards Lifesciences during Q2, citing strong Q3 earnings with $0.67 EPS and $1.55 billion in revenue, a 14.7% year-over-year rise. 同社は2025年度全額とQ4ガイドラインを提起し,アナリストは"モデレート・バイヤー"を実施し,平均価格目標は93.30ドル. The company raised 2025 full-year and Q4 guidance, while analysts maintained a “Moderate Buy” consensus with an average price target of $93.30. ポジティブな勢いにもかかわらず,インサイダーセールが起こり,経営陣は90日間で380万ドルの株を売却しました. Despite positive momentum, insider selling occurred, with executives selling $3.8 million in shares over 90 days. 株式は83.06ドルで閉鎖 株式は48.2億ドルの市場キャップで. The stock closed at $83.06 with a market cap of $48.2 billion.